Where Does Zosano Pharma Corp (ZSAN) Stock Fall in the Biotechnology Field?

Tuesday, August 4, 2020 2:23 PM | InvestorsObserver Analysts

Zosano Pharma Corp (ZSAN) is near the bottom in its industry group according to InvestorsObserver. ZSAN gets an overall rating of 40. That means it scores higher than 40 percent of stocks. Zosano Pharma Corp gets a 28 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Overall Score - 40
ZSAN has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on ZSAN!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Zosano Pharma Corp Stock Today?

Zosano Pharma Corp (ZSAN) stock is trading at $1.21 as of 2:20 PM on Tuesday, Aug 4, a rise of $0.16, or 15.25% from the previous closing price of $1.05. The stock has traded between $1.04 and $1.24 so far today. Volume today is above average. So far 9,871,958 shares have traded compared to average volume of 2,702,102 shares.

To see the top 5 stocks in Biotechnology click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Analyst Rating: Will Arcturus Therapeutics Holdings Inc (ARCT) Stock Outperform the Market?

What is the Forecast Price for BioCardia Inc (BCDA) Stock?

How Does Concert Pharmaceuticals Inc (CNCE) Stock Rank on Wall Street?

Do Analysts Agree on Apellis Pharmaceuticals Inc (APLS) Stock's Target Price?

Do Analysts Expect Verastem Inc (VSTM) Stock to Rise?

Analyst Rating: Will Incyte Corporation (INCY) Stock Outperform the Market?

Related Companies